<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582347</url>
  </required_header>
  <id_info>
    <org_study_id>RB-UK-11-0017</org_study_id>
    <nct_id>NCT01582347</nct_id>
  </id_info>
  <brief_title>Transfer of Subjects From Subutex/Suboxone to RBP-6300</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Active-drug-controlled, Parallel-group, Multicentre Acceptability and Safety Study of the Transfer From Subutex/Suboxone to RBP-6300 in Opioid-dependent Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if opioid dependent subjects who are already receiving
      Subutex and/or Suboxone can transfer to RBP-6300. Upon completing the study, subjects will
      continue their pre-study prescribed dosage of Subutex and/or Suboxone
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the open-label Run-In Period (study days -7 to -1), participants receive
      Subutex®/Suboxone® at one of three dose levels, depending on the dose level for that subject
      on entry to the study: 8 mg/day, 16 mg/day, or 24 mg/day.

      During the 7-day, active drug-controlled, double-blind Transfer Period (study days 1-7),
      participants are randomized to either Subutex®/Suboxone® or RBP-6300 active drug at dosing
      levels equivalent to the level during the Run-In Period plus placebo matching the other drug.

      This is followed by a 3-day single-blind Subutex®/Suboxone® Transition Period in which
      participants receive the same dose given during the Run-In Period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment</measure>
    <time_frame>7 days</time_frame>
    <description>To demonstrate that RBP-6300 is not inferior to Subutex/Suboxone as assessed by the peak change from baseline in the pre-dose COWS score during the double-blind transfer phase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the overall clinical response to RBP-6300</measure>
    <time_frame>one year</time_frame>
    <description>One of the secondary objectives is to evaluate the safety and tolerability of RBP-6300 in terms of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">143</enrollment>
  <condition>Opioid Related Disorder</condition>
  <arm_group>
    <arm_group_label>RBP-6300</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subutex®/Suboxone®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBP-6300</intervention_name>
    <description>Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).
Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate.</description>
    <arm_group_label>RBP-6300</arm_group_label>
    <other_name>buprenorphine hemiadipate HCl</other_name>
    <other_name>naloxone HCl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subutex®/Suboxone®</intervention_name>
    <description>Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.
Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.
Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.</description>
    <arm_group_label>RBP-6300</arm_group_label>
    <arm_group_label>Subutex®/Suboxone®</arm_group_label>
    <other_name>buprenorphine</other_name>
    <other_name>naloxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for RBP-6300</intervention_name>
    <description>Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.
Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.</description>
    <arm_group_label>RBP-6300</arm_group_label>
    <arm_group_label>Subutex®/Suboxone®</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for Subutex®/Suboxone®</intervention_name>
    <description>Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.</description>
    <arm_group_label>RBP-6300</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be Male or non-pregnant, non-lactating females

          -  Be at least 18 years of age

          -  Meet Diagnostic and Statistical Manual of Mental Disorders, DSM-IV-TR (Diagnostic and
             Statistical Manual-IV-TEXT REVISION)criteria for opioid dependence at screening

          -  Be on stable dose of 8, 16, or 24mg/day for about 30 days prior to screening

          -  Female subjects of childbearing potential must have a negative urine test prior to
             enrollment into the study

        Exclusion Criteria:

          -  Have participated in an experimental drug or device study within the last 60 days

          -  If female, be breast feeding or lactating

          -  Have any medical condition that in the opinion of the physician investigator would
             preclude the subject from completing the study

          -  Have a clinically significant abnormal finding (in the opinion of the investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norbert Scherbaum, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University, Duisburg-Essen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Wolzt, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ.-Klinik fur Klinische Pharmakologie, AKH Wien, Wien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Fleischhacker, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Innsbruck</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vratislav Rehak, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Remedis s.r.o., Prague</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zdenka Stankova, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masaryk Hospital Usti nad Labem</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver Pogarell, PD. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University, Munich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernd Weber, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis Dr. Bernd Weber am Koenigsplatz Schwerpunkprax is fur Suchtmedizin, Kassel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edith Issler, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectomed GbR Zentrum fuer medizinische Studien, Stuttgart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wieland Tietje, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drs. Tieje, Heer &amp; Koc, Bremen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard Boniakowski, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychosoziale Begleitung - Praxis Boniakowski, Regensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlotte Rechenmacher, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis Dr. Rechenmacher, Oldenburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georgieva, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Spyridon Kilaidakis, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Örebro County</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Schubert, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Substitutionsambulanz Geinhausen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chaim Jellinek</last_name>
    <role>Principal Investigator</role>
    <affiliation>a.i.d., Ambulanz fur integrierte Drogenhilfe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl Heinz Meller, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Praxis Dr. Meller</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Dr. Fleischhacker</name>
      <address>
        <city>Austria</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Lindenbauer</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Wurst</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Wolzt</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Vehak</name>
      <address>
        <city>Prague</city>
        <zip>1400</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Stankova</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40113</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Tietje</name>
      <address>
        <city>Bremen</city>
        <zip>28719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Scherbaum</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Weber</name>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PD. Dr. Pogarell</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rechenmacher</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Boniakowski</name>
      <address>
        <city>Regensburg</city>
        <zip>93051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Issler</name>
      <address>
        <city>Stuttgart</city>
        <zip>70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Kilaidakis</name>
      <address>
        <city>Orebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Georgieva</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <disposition_first_submitted>August 7, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 7, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 24, 2015</disposition_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

